Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer.

Liu S, Matsuzaki J, Wei L, Tsuji T, Battaglia S, Hu Q, Cortes E, Wong L, Yan L, Long M, Miliotto A, Bateman NW, Lele SB, Chodon T, Koya RC, Yao S, Zhu Q, Conrads TP, Wang J, Maxwell GL, Lugade AA, Odunsi K.

J Immunother Cancer. 2019 Jun 20;7(1):156. doi: 10.1186/s40425-019-0629-6.

2.

A rare population of tumor antigen-specific CD4+CD8+ double-positive αβ T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells.

Matsuzaki J, Tsuji T, Chodon T, Ryan C, Koya RC, Odunsi K.

J Immunother Cancer. 2019 Jan 9;7(1):7. doi: 10.1186/s40425-018-0467-y.

3.

Emerging Role and Future Directions of Immunotherapy in Advanced Ovarian Cancer.

Chodon T, Lugade AA, Battaglia S, Odunsi K.

Hematol Oncol Clin North Am. 2018 Dec;32(6):1025-1039. doi: 10.1016/j.hoc.2018.07.011. Epub 2018 Oct 1. Review.

PMID:
30390758
4.

Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products.

Nowicki TS, Escuin-Ordinas H, Avramis E, Chmielowski B, Chodon T, Berent-Maoz B, Wang X, Kaplan-Lefko P, Yang L, Baltimore D, Economou JS, Ribas A, Comin-Anduix B.

J Immunother. 2018 Jun;41(5):248-259. doi: 10.1097/CJI.0000000000000216.

5.

PD-1 Blockade Expands Intratumoral Memory T Cells.

Ribas A, Shin DS, Zaretsky J, Frederiksen J, Cornish A, Avramis E, Seja E, Kivork C, Siebert J, Kaplan-Lefko P, Wang X, Chmielowski B, Glaspy JA, Tumeh PC, Chodon T, Pe'er D, Comin-Anduix B.

Cancer Immunol Res. 2016 Mar;4(3):194-203. doi: 10.1158/2326-6066.CIR-15-0210. Epub 2016 Jan 19.

6.

Active Immunotherapy of Cancer.

Chodon T, Koya RC, Odunsi K.

Immunol Invest. 2015;44(8):817-36. doi: 10.3109/08820139.2015.1096684. Review.

PMID:
26575466
7.

HSV-sr39TK positron emission tomography and suicide gene elimination of human hematopoietic stem cells and their progeny in humanized mice.

Gschweng EH, McCracken MN, Kaufman ML, Ho M, Hollis RP, Wang X, Saini N, Koya RC, Chodon T, Ribas A, Witte ON, Kohn DB.

Cancer Res. 2014 Sep 15;74(18):5173-83. doi: 10.1158/0008-5472.CAN-14-0376. Epub 2014 Jul 18.

8.

Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.

Atefi M, Avramis E, Lassen A, Wong DJ, Robert L, Foulad D, Cerniglia M, Titz B, Chodon T, Graeber TG, Comin-Anduix B, Ribas A.

Clin Cancer Res. 2014 Jul 1;20(13):3446-57. doi: 10.1158/1078-0432.CCR-13-2797. Epub 2014 May 8.

9.

Exposure to a histone deacetylase inhibitor has detrimental effects on human lymphocyte viability and function.

Wong DJ, Rao A, Avramis E, Matsunaga DR, Komatsubara KM, Atefi MS, Escuin-Ordinas H, Chodon T, Koya RC, Ribas A, Comin-Anduix B.

Cancer Immunol Res. 2014 May;2(5):459-68. doi: 10.1158/2326-6066.CIR-13-0188. Epub 2014 Jan 30.

10.

Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma.

Chodon T, Comin-Anduix B, Chmielowski B, Koya RC, Wu Z, Auerbach M, Ng C, Avramis E, Seja E, Villanueva A, McCannel TA, Ishiyama A, Czernin J, Radu CG, Wang X, Gjertson DW, Cochran AJ, Cornetta K, Wong DJ, Kaplan-Lefko P, Hamid O, Samlowski W, Cohen PA, Daniels GA, Mukherji B, Yang L, Zack JA, Kohn DB, Heath JR, Glaspy JA, Witte ON, Baltimore D, Economou JS, Ribas A.

Clin Cancer Res. 2014 May 1;20(9):2457-65. doi: 10.1158/1078-0432.CCR-13-3017. Epub 2014 Mar 14.

11.

CTLA4 blockade broadens the peripheral T-cell receptor repertoire.

Robert L, Tsoi J, Wang X, Emerson R, Homet B, Chodon T, Mok S, Huang RR, Cochran AJ, Comin-Anduix B, Koya RC, Graeber TG, Robins H, Ribas A.

Clin Cancer Res. 2014 May 1;20(9):2424-32. doi: 10.1158/1078-0432.CCR-13-2648. Epub 2014 Feb 28. Erratum in: Clin Cancer Res. 2015 Jul 15;21(14):3359.

12.

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.

Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, Kelley MC, Kefford RF, Chmielowski B, Glaspy JA, Sosman JA, van Baren N, Long GV, Ribas A, Lo RS.

Cancer Discov. 2014 Jan;4(1):80-93. doi: 10.1158/2159-8290.CD-13-0642. Epub 2013 Nov 21.

13.

A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.

Shi H, Hong A, Kong X, Koya RC, Song C, Moriceau G, Hugo W, Yu CC, Ng C, Chodon T, Scolyer RA, Kefford RF, Ribas A, Long GV, Lo RS.

Cancer Discov. 2014 Jan;4(1):69-79. doi: 10.1158/2159-8290.CD-13-0279. Epub 2013 Nov 21.

14.

Natural killer T cells in advanced melanoma patients treated with tremelimumab.

Ibarrondo FJ, Yang OO, Chodon T, Avramis E, Lee Y, Sazegar H, Jalil J, Chmielowski B, Koya RC, Schmid I, Gomez-Navarro J, Jamieson BD, Ribas A, Comin-Anduix B.

PLoS One. 2013 Oct 22;8(10):e76829. doi: 10.1371/journal.pone.0076829. eCollection 2013.

15.

Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy.

Ma C, Cheung AF, Chodon T, Koya RC, Wu Z, Ng C, Avramis E, Cochran AJ, Witte ON, Baltimore D, Chmielowski B, Economou JS, Comin-Anduix B, Ribas A, Heath JR.

Cancer Discov. 2013 Apr;3(4):418-29. doi: 10.1158/2159-8290.CD-12-0383. Epub 2013 Mar 21.

16.

Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM·CAIX in immunocompetent mouse models.

Birkhäuser FD, Koya RC, Neufeld C, Rampersaud EN, Lu X, Micewicz ED, Chodon T, Atefi M, Kroeger N, Chandramouli GV, Li G, Said JW, McBride WH, Kabbinavar FF, Ribas A, Pantuck AJ, Belldegrun AS, Riss J.

J Immunother. 2013 Feb;36(2):102-11. doi: 10.1097/CJI.0b013e31827bec97.

17.

BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy.

Koya RC, Mok S, Otte N, Blacketor KJ, Comin-Anduix B, Tumeh PC, Minasyan A, Graham NA, Graeber TG, Chodon T, Ribas A.

Cancer Res. 2012 Aug 15;72(16):3928-37. doi: 10.1158/0008-5472.CAN-11-2837. Epub 2012 Jun 12.

18.

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance.

Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, Ng C, Chodon T, Scolyer RA, Dahlman KB, Sosman JA, Kefford RF, Long GV, Nelson SF, Ribas A, Lo RS.

Nat Commun. 2012 Mar 6;3:724. doi: 10.1038/ncomms1727.

19.

A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cells.

Ma C, Fan R, Ahmad H, Shi Q, Comin-Anduix B, Chodon T, Koya RC, Liu CC, Kwong GA, Radu CG, Ribas A, Heath JR.

Nat Med. 2011 Jun;17(6):738-43. doi: 10.1038/nm.2375. Epub 2011 May 22.

20.

The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations.

Comin-Anduix B, Chodon T, Sazegar H, Matsunaga D, Mock S, Jalil J, Escuin-Ordinas H, Chmielowski B, Koya RC, Ribas A.

Clin Cancer Res. 2010 Dec 15;16(24):6040-8. doi: 10.1158/1078-0432.CCR-10-1911.

21.

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.

Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS.

Nature. 2010 Dec 16;468(7326):973-7. doi: 10.1038/nature09626. Epub 2010 Nov 24.

22.

Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma.

Comin-Anduix B, Sazegar H, Chodon T, Matsunaga D, Jalil J, von Euw E, Escuin-Ordinas H, Balderas R, Chmielowski B, Gomez-Navarro J, Koya RC, Ribas A.

PLoS One. 2010 Sep 15;5(9):e12711. doi: 10.1371/journal.pone.0012711.

23.

The impact of ex vivo clinical grade activation protocols on human T-cell phenotype and function for the generation of genetically modified cells for adoptive cell transfer therapy.

Tumeh PC, Koya RC, Chodon T, Graham NA, Graeber TG, Comin-Anduix B, Ribas A.

J Immunother. 2010 Oct;33(8):759-68. doi: 10.1097/CJI.0b013e3181f1d644.

24.

Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses.

Koya RC, Mok S, Comin-Anduix B, Chodon T, Radu CG, Nishimura MI, Witte ON, Ribas A.

Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14286-91. doi: 10.1073/pnas.1008300107. Epub 2010 Jul 12.

25.

MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro.

Ray S, Chhabra A, Chakraborty NG, Hegde U, Dorsky DI, Chodon T, von Euw E, Comin-Anduix B, Koya RC, Ribas A, Economou JS, Rosenberg SA, Mukherji B; UCLA-CALTECH-CHLA-USC-UCONN Consortium on Translational Program in Engineered Immunity.

Clin Immunol. 2010 Sep;136(3):338-47. doi: 10.1016/j.clim.2010.04.013. Epub 2010 May 23.

26.

CTLA4 blockade increases Th17 cells in patients with metastatic melanoma.

von Euw E, Chodon T, Attar N, Jalil J, Koya RC, Comin-Anduix B, Ribas A.

J Transl Med. 2009 May 20;7:35. doi: 10.1186/1479-5876-7-35.

27.
28.

Identification of a novel gelsolin truncate in the vertical and metastatic phase malignant melanomas.

Furukawa H, Fujita H, Kokubu I, Yamamoto Y, Sasaki S, Chodon T, Okubo Y, Sugihara T, Kuzumaki N.

Melanoma Res. 2002 Dec;12(6):523-8.

PMID:
12459641
29.
30.

Intravenous chloramphenicol plus penicillin versus intramuscular ceftriaxone for the treatment of pyogenic meningitis in Nepalese children.

Sharma PR, Adhikari RK, Joshi MP, Lal M, Chodon T, Pokhrel BM, Shrestha RS, Shrestha IB.

Trop Doct. 1996 Apr;26(2):84-5. No abstract available.

PMID:
8685976

Supplemental Content

Loading ...
Support Center